Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» GlaxoSmithKline's 4.8% Yield Makes It Attractive With Or Without Human Genome Takeover
GlaxoSmithKline's 4.8% Yield Makes It Attractive With Or Without Human Genome Takeover
GlaxoSmithKline's 4.8% Yield Makes It Attractive With Or Without Human Genome Takeover
Submitted by
admin
on May 15, 2012 - 10:40am
Source:
Seeking Alpha
News Tags:
GSK
Human Genome Sciences
Novartis
Pfizer
Roche
Headline:
GlaxoSmithKline's 4.8% Yield Makes It Attractive With Or Without Human Genome Takeover
Do Not Allow Advertisers to Use My Personal information
